Larimar Therapeutics received new analyst coverage from Citigroup, which reiterated a buy rating, alongside market data updates.
1 report, 1 independent
Updated Sep 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Larimar Therapeutics received new analyst coverage from Citigroup, which reiterated a buy rating, alongside market data updates.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
MarketBeat
American personal finance blog
-
Citigroup
American investment bank and financial services corporation
Related events
- MarketBeat provides stock rating data for Vivos Therapeutics, which is listed on Nasdaq.
- MarketBeat published average ratings and price targets for Kalaris Therapeutics, while Citigroup reaffirmed an outperform rating and TD Cowen initiated coverage with a buy rating.
- MarketBeat provided an average rating and target price for Tenaya Therapeutics.
- MarketBeat has published analyst ratings and financial data for two companies: Werewolf Therapeutics, Inc. and ADMA Biologics, Inc.
- MarketBeat reported on the stock performance of Allarity Therapeutics, Inc. on September 1, 2026.